HCW Biologics Receive FDA Clearance For Alopecia Areata Trial

HCW Biologics has received FDA clearance to start a first-in-human safety trial for their potential alopecia areata treatment, HCW9302.  Who Are HCW Biologics? HCW Biologics Inc. is a clinical-stage biopharmaceutical company based in Miramar, Florida. The company focuses on developing immunotherapies targeting chronic inflammation in age-related diseases like cancer, autoimmune disorders, and neurodegenerative conditions. The…

Read More

Eirion Therapeutics Announces First-in-Human Trial Results for ET-02 in Androgenic Alopecia

After a slow and disappointing winter season in 2024, we start the year with some positive news in the androgenic alopecia space. Eirion Therapeutics, a clinical-stage biopharmaceutical company with oral and topical androgenic alopecia treatments in the pipeline, has announced results from their 4-week androgenic alopecia trial of topical ET-02. What Is ET-02? We don’t…

Read More

Sun Pharma Reveals Efficacy Data for Deuruxolitinib for Alopecia Areata

Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…

Read More

Amplifica Reveals Results from Its First-in-Human Trial For Androgenic Alopecia

Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3). What is AMP-303? We spoke about AMP-303 last year when they announced the initiation…

Read More

FDA Approves Deuruxolitinib for Severe Alopecia Areata

The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults.  What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…

Read More

Dermaliq Announced Results From its Phase 1b/2a Trial For DLQ01 For Androgenic Alopecia

Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men.  What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…

Read More

TOP-M119: Topadur Pharma and Oshen Holdings To Develop New Androgenic Alopecia Treatment

Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il  Messaggero, quote “The most curious thing is that the currently candidate drug,…

Read More